720720-27-4 Usage
Heterocyclic compound
A compound containing a ring structure with at least one heteroatom (an atom other than carbon) as part of the ring, in this case, the fused pyrrolopyridine ring system.
Fused pyrrolopyridine ring system
A structure formed by the connection of a pyrrole and a pyridine ring sharing a common pair of carbon atoms, resulting in a unique and stable ring system.
Carboxylic acid derivative
A compound derived from a carboxylic acid by replacing the hydroxyl group (-OH) with another functional group, in this case, the 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine structure.
Carboxyl group
A functional group consisting of a carbonyl group (C=O) and a hydroxyl group (-OH) bonded to the same carbon atom, represented as -COOH in the compound.
Potential applications in pharmaceutical and agrochemical industries
The unique ring system and functional groups of 1H-Pyrrolo[3,4-c]pyridine-6-carboxylicacid,2,3-dihydro-(9CI) make it a promising candidate for the development of new drugs and agrochemical products due to its potential pharmacological properties and biological activities.
Synthesis and utilization in drug discovery
The process of creating and modifying the compound to identify its potential therapeutic effects and applications in the development of new medications.
Pharmacological properties
The set of pharmacological effects and interactions that the compound may have with biological systems, which can be studied to determine its potential as a therapeutic agent.
Potential biological activities
The possible effects that the compound may have on living organisms, which can be investigated to understand its potential applications in medicine and other fields.
Check Digit Verification of cas no
The CAS Registry Mumber 720720-27-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,2,0,7,2 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 720720-27:
(8*7)+(7*2)+(6*0)+(5*7)+(4*2)+(3*0)+(2*2)+(1*7)=124
124 % 10 = 4
So 720720-27-4 is a valid CAS Registry Number.
720720-27-4Relevant articles and documents
TARGETING COMPOUNDS
-
Paragraph 0413; 0418, (2019/07/19)
The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
NOVEL ETHYLENEDIAMINE DERIVATIVES
-
Page/Page column 90, (2010/02/14)
A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
